WASHINGTON DC (June 30, 2021) – AAM applauds Governor Janet Mills (D-ME) for protecting Maine patients’ access to safe, affordable generic medicines by vetoing LD 1117. Governor Mill’s decision to veto this bill on constitutional grounds was the right choice to make. LD 1117 misdiagnosed the problem of high prescription drug costs. Generic medicines save patients in Maine more than $1 billion a year. Ensuring access to generic medicines – as the Governor’s veto of LD 1117 accomplishes – is the solution to lowering the cost of prescription drugs.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.